Press release
Wet Age-Related Macular Degeneration Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, IVERIC bio, Ribomic, Curacle, Bio-Thera Solutions, Ang
The Wet Age-Related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Wet Age-Related Macular Degeneration Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration Market.
Some of the key takeaways from the Wet Age-Related Macular Degeneration Pipeline Report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Wet Age-Related Macular Degeneration treatment therapies with a considerable amount of success over the years.
• Wet Age-Related Macular Degeneration companies working in the treatment market are Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others, are developing therapies for the Wet Age-Related Macular Degeneration treatment
• Emerging Wet Age-Related Macular Degeneration therapies in the different phases of clinical trials are- ONS-5010, OPT-302, SYL1801, BI 836880, NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others are expected to have a significant impact on the Wet Age-Related Macular Degeneration market in the coming years.
• In March 2025, Opthea has decided to halt its COAST and ShORe clinical trials for wet age-related macular degeneration (AMD) after the COAST study failed to achieve its primary endpoint. The company also expedited the release of topline data from the ShORe trial, which similarly did not meet its primary goal of improving best corrected visual acuity (BCVA) from baseline to week 52. The global Phase 3 ShORe study assessed the efficacy and safety of intravitreal 2 mg sozinibercept administered every 4 or 8 weeks alongside 0.5 mg ranibizumab every 4 weeks, compared to ranibizumab monotherapy.
• In December 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), focused on advancing innovative treatments for serious retinal conditions, announced the dosing of the first patient in its LUCIA trial-its second global Phase 3 study evaluating DURAVYU (formerly EYP-1901) for wet age-related macular degeneration (wet AMD). DURAVYU is an investigational sustained-release therapy that delivers vorolanib, a selective tyrosine kinase inhibitor, using the company's proprietary bioerodible Durasert ETM technology for long-acting intraocular delivery.
• In July 2024, NexThera Co., Ltd. (CEO SaeGwang Park) announced the submission of a Phase 1/2a Investigational New Drug (IND) application to the U.S. FDA for NT-101, an eye drop therapy designed to treat wet age-related macular degeneration (wet AMD). NT-101 is the company's first drug candidate developed through its proprietary eye drop delivery technology, offering a non-invasive alternative to traditional intraocular injections for delivering treatment to retinal tissue.
Wet Age-Related Macular Degeneration Overview
Wet Age-Related Macular Degeneration (Wet AMD) is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It occurs when abnormal blood vessels grow under the macula, the part of the retina responsible for sharp, central vision.
Get a Free Sample PDF Report to know more about Wet Age-Related Macular Degeneration Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Wet Age-Related Macular Degeneration Drugs Under Different Phases of Clinical Development Include:
• ONS-5010: Outlook Therapeutics
• OPT-302: Opthea
• SYL1801: Sylentis
• BI 836880: Boehringer Ingelheim
• NNG101 AAV gene therapy: Neuracle Genetics, Inc
• Eyp-1901: EyePoint Pharmaceuticals, Inc.
• RC28-E: RemeGen Co., Ltd.
• bevacizumab: Outlook Therapeutics
• Ranibizumab: Sinocelltech Ltd.
• MW02: Mabwell (Shanghai) Bioscience
• 4D-150 IVT: 4D Molecular Therapeutics
• Aflibercept: Michel Giunta
• BAT5906 injection: Bio-Thera Solutions
• SYL1801: Sylentis, S.A.
• HLX04-O: Shanghai Henlius Biotech
• ADVM-022: Adverum Biotechnologies, Inc.
• OTX-TKI (axitinib implant): Ocular Therapeutix, Inc.
• CLS-AX: Clearside Biomedical, Inc.
• SKG0106: Skyline Therapeutics
• AXT107: AsclepiX Therapeutics
• Iptacopan (LNP023): Novartis
• RRG001: Shanghai Refreshgene Tech
• EXG102-031: Hangzhou Jiayin Biotech Ltd
• TAB014: TOT Biopharm Co., Ltd.
• Faricimab: Hoffmann-La RocheLUCENTIS (ranibizumab injection): Genentech, Inc.
• Aflibercept Ophthalmic: Innovent Biologics (Suzhou) Co. Ltd.
• GNR-067: AO GENERIUM
• BAY86-5321: Bayer
Wet Age-Related Macular Degeneration Route of Administration
Wet Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Wet Age-Related Macular Degeneration Molecule Type
Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment
• Wet Age-Related Macular Degeneration Assessment by Product Type
• Wet Age-Related Macular Degeneration By Stage and Product Type
• Wet Age-Related Macular Degeneration Assessment by Route of Administration
• Wet Age-Related Macular Degeneration By Stage and Route of Administration
• Wet Age-Related Macular Degeneration Assessment by Molecule Type
• Wet Age-Related Macular Degeneration by Stage and Molecule Type
DelveInsight's Wet Age-Related Macular Degeneration Report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Wet Age-Related Macular Degeneration product details are provided in the report. Download the Wet Age-Related Macular Degeneration pipeline report to learn more about the emerging Wet Age-Related Macular Degeneration therapies
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Wet Age-Related Macular Degeneration Therapeutics Market include:
Key companies developing therapies for Wet Age-Related Macular Degeneration are - IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, and others.
Wet Age-Related Macular Degeneration Pipeline Analysis:
The Wet Age-Related Macular Degeneration pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Wet Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration Treatment.
• Wet Age-Related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet Age-Related Macular Degeneration market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Wet Age-Related Macular Degeneration drugs and therapies
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Wet Age-Related Macular Degeneration Pipeline Market Drivers
• Rise in ageing population, entry of biosimilars, robust pipeline are some of the important factors that are fueling the Wet Age-Related Macular Degeneration Market.
Wet Age-Related Macular Degeneration Pipeline Market Barriers
• However, burden of medical treatment, high cost associated with antiVEGF agents, decrease in quality of life and other factors are creating obstacles in the Wet Age-Related Macular Degeneration Market growth.
Scope of Wet Age-Related Macular Degeneration Pipeline Drug Insight
• Coverage: Global
• Key Wet Age-Related Macular Degeneration Companies: Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others
• Key Wet Age-Related Macular Degeneration Therapies: ONS-5010, OPT-302, SYL1801, BI 836880, NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others
• Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers
Request for Sample PDF Report for Wet Age-Related Macular Degeneration Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Wet Age-Related Macular Degeneration Report Introduction
2. Wet Age-Related Macular Degeneration Executive Summary
3. Wet Age-Related Macular Degeneration Overview
4. Wet Age-Related Macular Degeneration- Analytical Perspective In-depth Commercial Assessment
5. Wet Age-Related Macular Degeneration Pipeline Therapeutics
6. Wet Age-Related Macular Degeneration Late Stage Products (Phase II/III)
7. Wet Age-Related Macular Degeneration Mid Stage Products (Phase II)
8. Wet Age-Related Macular Degeneration Early Stage Products (Phase I)
9. Wet Age-Related Macular Degeneration Preclinical Stage Products
10. Wet Age-Related Macular Degeneration Therapeutics Assessment
11. Wet Age-Related Macular Degeneration Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Wet Age-Related Macular Degeneration Key Companies
14. Wet Age-Related Macular Degeneration Key Products
15. Wet Age-Related Macular Degeneration Unmet Needs
16 . Wet Age-Related Macular Degeneration Market Drivers and Barriers
17. Wet Age-Related Macular Degeneration Future Perspectives and Conclusion
18. Wet Age-Related Macular Degeneration Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Wet Age-Related Macular Degeneration Market https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Wet Age-Related Macular Degeneration Epidemiology https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wet Age-Related Macular Degeneration Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Wet Age-Related Macular Degeneration Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, IVERIC bio, Ribomic, Curacle, Bio-Thera Solutions, Ang here
News-ID: 4128728 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Wet
Wet Age-Related Macular Degeneration (Wet AMD) market is expected to reach USD 1 …
Wet age-related macular degeneration (Wet AMD) is a chronic, progressive eye disorder and one of the leading causes of severe vision loss in people over 60. Unlike the dry form of AMD, Wet AMD is characterized by the growth of abnormal blood vessels under the retina that leak fluid or blood, leading to rapid central vision loss. While Wet AMD accounts for only about 10-15% of all AMD cases, it…
Wet And Cold Appliance Market Size Analysis by Application, Type, and Region: Fo …
USA, New Jersey- According to Market Research Intellect, the global Wet And Cold Appliance market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The wet and cold appliance market is expanding steadily, driven by changing consumer lifestyles, increasing urbanization, and rising demand for home automation. Appliances…
Semiconductor Electronic Wet Chemicals Market
Semiconductor Electronic Wet Chemicals Market Overview
Electronic wet chemicals are ultra-pure nature due to which they are extensively used in cleaning and etching application during semiconductor production and processing.
This report provides a deep insight into the global Semiconductor Electronic Wet Chemicals market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market…
Wet and Dry Vacuum Cleaner Market
The "Wet and Dry Vacuum Cleaner Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Wet and Dry Vacuum Cleaner Market, 2024-2031
Verified Market Research's most recent report, "Wet and Dry Vacuum Cleaner Market: Global Industry Trends, Share, Size,…
Wet Filtered Downdraught Workbench Market
Wet filtered downdraught workbench is the industry's leading solution for the collection of combustible metal dust which can safely removes combustible materials while complying with NFPA and OSHA combustible dust guidelines.
The global Wet Filtered Downdraught Workbench market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine…
Corn Wet-milling Market Corn Wet Milling Market Share, Size, Demand, Key Players …
Market Analysis and Insights of Global Corn Wet-milling Market
The corn wet-milling market is expected to witness market growth at a rate of 5.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on corn wet-milling market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The growth in awareness globally is…
